You are about to leave
this Takeda website
Takeda has no control over the content or presentation of the third-party site you are about to view.
Patient portrayal
Learn more about Vyvanse and take a look at how it performed in clinical studies.
Vyvanse may help increase attention, and decrease impulsiveness and hyperactivity in adults with ADHD. Your doctor may prescribe Vyvanse as part of a total treatment program that may include counseling or other therapies.
142 adults aged 18-55 years with ADHD.
For the first 4 weeks, everyone in the study took Vyvanse. Researchers adjusted the dose as needed to find the right dose for each person.
At the beginning of the fifth week, half of the group continued to take Vyvanse. The other half switched to sugar pill (placebo). Researchers and subjects didn’t know who got Vyvanse and who got the sugar pill.
At the end of the fifth week, during a single day, both groups were placed in a classroom-like setting designed to resemble the workplace environment.
At 7 AM, everyone took their assigned medication—either Vyvanse or the sugar pill. Next, they began a schedule of general activities that were designed to keep study subjects busy and bring out symptoms of ADHD. After each set of activities, subjects were given the PERMP* test, which is commonly used by researchers to measure attention in ADHD. Tests were given over 14 hours at 9 AM, 11 AM, 3 PM, 5 PM, and 7 PM; the last test was at 9 PM.
*PERMP=Permanent Product Measure of Performance, a skill-adjusted math test that measures attention in ADHD. PERMP is not a test of the ability to learn math.
At the beginning of the sixth week, the group that had taken Vyvanse was switched to the sugar pill, and the group that had taken the sugar pill was switched to Vyvanse. At the end of the sixth week, study subjects were again given the timed tests under the same conditions across the day.
Attention was measured by using the groups’ average test scores throughout the day when taking Vyvanse compared to when taking the sugar pill. Higher scores indicated improved attention.
The average of all scores throughout the day was higher when Vyvanse was taken. Vyvanse improved attention throughout the day for each timepoint tested, starting at 2 hours, and even at 14 hours after taking it.†
†Efficacy measured using the Permanent Product Measure of Performance (PERMP), a skill-adjusted math test that measures attention in ADHD. PERMP is not a test of the ability to learn math.
420 adult subjects aged 18-55 years with ADHD
Patients were divided into 4 groups, receiving Vyvanse 30 mg, 50 mg, or 70 mg, or sugar pill.
Patients assigned to the Vyvanse 30 mg treatment group received this amount for 4 weeks. Patients assigned to Vyvanse 50 mg treatment received 30 mg in the first week and 50 mg for the next 3 weeks. Patients assigned to Vyvanse 70 mg treatment received 30 mg in the first week, 50 mg in the second week, and 70 mg in the next 2 weeks.
Clinicians measured symptom level in patients at the start of the study and during every week using the ADHD-RS-IV measurement. Lower scores on the ADHD-RS-IV indicate better symptom control. Study results were based on average change in ADHD-RS-IV total score of all doses tested.
People treated with Vyvanse showed twice the symptom improvement compared to people who were treated with a sugar pill.‡
‡Results based on the Attention-Deficit/Hyperactivity Disorder Rating Scale, Version IV (ADHD-RS-IV), an investigator-rated measure of the core symptoms of ADHD.
§P<.0001 for Vyvanse vs placebo at endpoint.
Vyvanse should be taken exactly as prescribed by your doctor. Before starting Vyvanse and during treatment, tell your doctor about all health conditions (or family history of) including:
123 adults aged 18 to 55 with ADHD. Treated with Vyvanse for at least 6 months, and demonstrated a response to Vyvanse treatment with low Total Score on the ADHD Rating Scale IV (ADHD-RS-IV) and on the CGI-S.‖
‖CGI-S=Clinical Global Impressions Severity, an investigator-rated evaluation of the severity of the patient's illness at the time of assessment.
The first part of the study was 3 weeks long. The second part was 6 weeks long.
In the first part, all patients continued taking their Vyvanse daily dose for 3 weeks. In the second part, half the patients were switched to sugar pill while the other half continued on Vyvanse. This part was double-blinded, meaning neither the patients nor the clinicians knew which patients received Vyvanse and which received the sugar pill.
Clinicians measured symptom control in patients at the start of the study and every week using the ADHD-RS-IV Total Score measurement. Lower scores on the ADHD-RS-IV indicate better symptom control. The Clinical Global Impression-Severity (CGI-S) score was also measured.
At the end of the study, 91% of people maintained ADHD symptom control with Vyvanse versus 25% with a sugar pill.¶
¶Treatment failure was defined as a ≥50% increase (worsening) in the ADHD Rating Scale IV (ADHD-RS-IV) Total Score and ≥2-point increase in the Clinical Global Impression Severity (CGI-S) score compared to scores at entry into the double-blind phase.
Information to help prepare you for a conversation with your doctor.
Learn more about dosing and administration for Vyvanse.
